Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- HEALTH SERVICES ADMINISTRATION
- MEDICAL ONCOLOGY
- PHARMACEUTICAL PREPARATIONS
- PHARMACY SERVICE, HOSPITAL
According to the Summary of Product Characteristics,1 capecitabine is indicated for locally advanced or metastatic breast cancer in combination with docetaxel after cytotoxic chemotherapy has failed (the previous treatment must have included an anthracycline), in monotherapy after taxanes and anthracycline have failed, or for patients for whom continuing with anthracycline treatment is not indicated.
Its adjuvant indication in non-pathological complete response triple-negative breast cancer with residual disease after neoadjuvant therapy and surgery (progression after taxane) was associated with increased …
Twitter @anaicp, @lvilpin1
Contributors AICP designed the study and made primary contributions to data collection. LVP, CASF and IFS assisted with data collection. Guarantor: AICP.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.